AusBiotech was pleased to be invited to participate in a HealthTech Roundtable and Business Luncheon with the Hong Kong Government's Financial Secretary, Mr. Paul Chan, and members to discuss growth opportunities for Australian biotech in Hong Kong and Asia.
The roundtable, organised by Hong Kong Economic Trade Office and InvestHK, attracted attendees from a wide range of stakeholders including investors, start-ups, industry, professional services companies and business associations.
AusBiotech and its members had the opportunity to hear about the latest updates on the innovation and technology initiatives in Hong Kong, as well as discuss issues that they face in an interactive roundtable discussion.
With more than 100 people in attendance, the day included a business luncheon themed 'Hong Kong's advantages as an innovation and technology hub', which included a keynote and Q&A with Mr Chan, and a panel discussion with fintech scaleups and technology investors.
The roundtable discussion, themed 'The development of Health Technology in Australia and Hong Kong as an innovation hub for global expansion', explored opportunities for Australian healthtech innovators looking to expand key Asian markets like Hong Kong, and partnering with Hong Kong businesses and investors to develop commercial biomedical products, and recognised the strength of Australian innovation in this field.
This roundtable provided an excellent opportunity for companies involved in the health and medical sector to understand first-hand the latest updates on the innovation and technology initiatives in Hong Kong, as well as the support available from the Hong Kong Government for foreign investors.
Mr. Chan, the Finance Minister of Hong Kong, oversees the use of public funds in Hong Kong as well as how resources should be channelled to fuel the grow of the innovation and technology industry.
Thank you to our members who participated in the roundtable, including: 360biolabs' Sharon Sim, AdAlta's (ASX:1AD) Tim Oldham, Chimeric Therapeutics' (ASX:CHM) Rebecca McQualter, and EZZ LifeSciences' (ASX: EZZ) Glenn Cross.
AusBiotech's engagement with InvestHK and the Hong Kong Economic Trade Office is part of its global strategy to facilitate international opportunities for investment, collaborations and partnerships, focusing on the markets important to members, as highlighted in AusBiotech's Strategic Plan 2021-2024.
AusBiotech is committed to supporting these ongoing opportunities for industry, which are crucial for the growth of the Australian life sciences sector, and, ultimately for continuing Australia's position in the sector globally.
